Processing...
Clinical Trials for Esophageal Cancer
Search
Search
There are 99 active trials for advanced/metastatic esophageal cancer.
Click on a trial to see more information.
99 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with previously treated unresectable or metastatic KRAS G12D–mutated solid tumors are eligible for dose escalation; dose expansion is limited to pancreatic ductal adenocarcinoma after at least one prior systemic therapy. All receive IV ARV-806, an investigational PROTAC designed to degrade mutant KRAS G12D, weekly or every two weeks.
ClinicalTrials.gov ID: NCT07023731
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors that have progressed after standard therapy or lack a standard option are eligible if at least one lesion shows uptake on [203Pb]Pb-PSV359 SPECT/CT. The imaging agent selects patients for treatment with [212Pb]Pb-PSV359, a FAP-targeted peptide that delivers alpha-particle radiation.
ClinicalTrials.gov ID: NCT06710756
TrialFetch AI summary: This trial enrolls previously treated patients with unresectable locally advanced, recurrent, or metastatic NSCLC, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, or left-sided colorectal cancer; prior treatment with a topoisomerase I inhibitor–payload ADC is excluded. All participants receive ALX2004, an investigational EGFR-targeting antibody–drug conjugate with a topoisomerase I inhibitor payload, at a dose determined by the study stage.
ClinicalTrials.gov ID: NCT07085091
TrialFetch AI summary: Patients with unresectable locally advanced or metastatic solid tumors harboring eligible AKT/PI3K/PTEN pathway alterations receive the investigational oral selective AKT1 inhibitor TER-2013 alone. Patients with HR-positive/HER2-negative advanced breast cancer previously treated with an aromatase inhibitor may receive TER-2013 with fulvestrant.
ClinicalTrials.gov ID: NCT07109726
TrialFetch AI summary: Adults with ECOG 0–1 and advanced/unresectable gastric/GEJ or esophageal adenocarcinoma (post ≥1 line), colorectal adenocarcinoma (post ≥2 lines; anti-EGFR if RAS WT), or hepatocellular carcinoma (treatment‑naive or previously treated) receive cabozantinib (MET/VEGFR2/AXL multikinase inhibitor) plus durvalumab (PD‑L1 inhibitor), with an HCC cohort also getting a single priming dose of tremelimumab (CTLA‑4 antibody). Baseline/on‑treatment biopsies required; prior PD‑1/PD‑L1 generally excluded except per HCC and gastric/esophageal protocol allowances.
ClinicalTrials.gov ID: NCT03539822
TrialFetch AI summary: Adults under 70 with metastatic gastrointestinal cancer that has progressed after standard chemotherapy, or who are ineligible for it, and an injectable tumor receive a single intratumoral injection of vvDD-hIL-2-RG-1. This oncolytic vaccinia virus is engineered for tumor-selective activity and expression of membrane-bound human IL-2 to stimulate antitumor T-cell responses.
ClinicalTrials.gov ID: NCT07001592
TrialFetch AI summary: Adults with metastatic or unresectable HER2‑negative adenocarcinoma of the esophagus/GEJ/stomach (no prior metastatic therapy; ECOG 0–2) receive an alternating doublet sFOLFOXIRI schedule: mFOLFOX6 on odd cycles and FOLFIRI on even cycles every 2 weeks. Optional nivolumab (PD‑1 inhibitor) may be added per label to enhance antitumor activity.
ClinicalTrials.gov ID: NCT05332002
TrialFetch AI summary: Adults with measurable, locally advanced or metastatic bladder cancer or squamous cell carcinoma of the lung, esophagus, skin, or anogenital region, generally after standard therapy, receive EVOLVE104 monotherapy. This investigational trispecific T-cell engager binds tumor-cell ULBP2/5/6 and T-cell CD3 and CD2 to promote T-cell killing with CD2 costimulation.
ClinicalTrials.gov ID: NCT07217171
TrialFetch AI summary: Adults with measurable advanced bladder, lung, head and neck, esophageal, or pancreatic cancer and ECOG 0–1 receive intravenous PF-08046876, an antibody–drug conjugate targeting integrin beta-6 that delivers a camptothecin-class topoisomerase I inhibitor. Dose escalation requires progression after standard therapy; dose optimization and expansion cohorts allow up to two prior systemic therapy lines for advanced disease.
ClinicalTrials.gov ID: NCT07090499
TrialFetch AI summary: Adults with measurable advanced solid tumors that have progressed after standard therapy or lack a standard treatment option receive a single intravenous infusion of IDOV-Immune. This engineered oncolytic vaccinia virus is designed to replicate preferentially in tumor cells, destroy them, and stimulate antitumor immunity.
ClinicalTrials.gov ID: NCT06910657